Weidemeier, Martin	FIS_84762
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
Duration of Surgery and Intraoperative Blood Pressure Management are Modifiable Risk Factors for Postoperative Neurocognitive Disorders Following Spine Surgery: Results of the Prospective CONFESS Study.